Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin.
Poorly Differentiated Thyroid Carcinoma (PDTC), especially advanced PDTC, is an aggressive disease and displays a much poorer prognosis compared with well differentiated thyroid carcinoma. Surgery is the recommended treatment in the early stage of PDTC, however, no effective treatment modalities are currently available for advanced PDTCMethods: Two advanced PDTC patients with no radioiodine uptake adopted a cytotoxic chemotherapy with liposomal doxorubicin (35 mg/m(2), day 1) plus cisplatin (75 mg/m(2), day1-3) every 3 weeks. Computer tomography (CT) was performed after 6 cycles (case 1) or 5 cycles (case 2) of chemotherapy



Our patients achieved remarkable response with one a Complete Remission (CR) and the other a very good Partial Remission (PR)Conclusion: Our findings indicate that liposomal doxorubicin-based chemotherapy regimens might produce response in PDTC patients, and improve their overall survival and quality of life. Hence we believe this result is very important for oncologists in treating PDTC.
a Chemotherapy Center, Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Haiyan
H
Yang
b Laboratory of Clinical Pharmacy, Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Zhongjian
Z
Chen
c Department of Pathology , Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Meijuan
M
Wu
a Chemotherapy Center, Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Tao
T
Lei
a Chemotherapy Center, Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Haifeng
H
Yu
d Department of Head and Neck Surgery , Zhejiang Province Cancer Hospital , Hangzhou , PR China.
Minghua
M
Ge
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002454:Cell Differentiation; D002945:Cisplatin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D002945:Cisplatin
Poorly differentiated thyroid carcinoma; chemotherapy; cis-platinum; complete remission; liposomal doxorubicin; partial remission